BioWorld Asia

Sep. 17, 2008

View Archived Issues

Blocking Heat Shock Proteins Points to More Selective Drugs

Unibioscreen Gets Up to $31M in Cancer Drug Deal with Drais

NicOx Shows Positive Data From 2nd Naproxcinod Trial

Polyplus-transfection Develops New Class of Oligonucleotides

Biomarker Data Point to Target Patients for Transgene's Vaccine

CV Therapeutics Gets $70M Up Front in Ex-U.S. Ranexa Deal

Other News To Note

Cell Medica Begins Study of CMV Transplant Therapy

LONDON - Cell Medica Ltd. has treated the first patient in a Phase III trial of a cell therapy treatment for the prevention of cytomegalovirus (CMV) infection in immunocompromised bone marrow transplant patients. (BioWorld International) Read More

HemoCORM, Alfama Align in Carbon Monoxide Deal

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

New biomarker may improve RSV drug screening

BioWorld

Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...